Evaluation of biopharmaceutical usefulness of cyclic-bis-desmosides, an amphiphilic inclusion compound
| Project/Area Number |
25460052
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Physical pharmacy
|
|---|
| Research Institution | Hiroshima International University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ODA Keisuke 広島国際大学, 薬学部, 助教 (60712594)
MORI Nobuhiro 広島国際大学, 医療栄養学部, 教授 (70412351)
堂官 留美子 広島国際大学, 薬学部, 助教 (20435069)
金子 哲夫 広島国際大学, 薬学部, 准教授 (00389107)
笠井 良次 広島国際大学, 薬学部, 教授 (10034018)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2014: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2013: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
|
|---|
| Keywords | サイクリックビスデスモシド / 難水溶性化合物 / 包接複合体 / 溶解度改善 / 吸収改善 / シクロデキストリン / サイクリックビスビスデスモシド / 両親媒性包接化合物 / 包接化合物 / 生物薬剤学的応用 / 生体膜透過 / 大環状構造 / 溶解補助剤 / 難水溶性薬物 / グリセオフルビン / イトラコナゾール / 経皮適用製剤 |
|---|
| Outline of Final Research Achievements |
Cyclic-bis-desmoside extracted from plants (T-1) is an amphiphilic compound having cyclic structure, indicating that T-1 is used as an inclusion compound, as well as the cases of various cyclodextrins (CD). In this study, itraconazole, orall administered medicine for the treatment of onychomycosis, was used as a model compound with poorly water soluble, and hydroxypropyl-β-CD (HP-β-CD) was used as a clinicalyl used potent inclusion compound for comparison. T-1 increased the water solubility of itraconazole approximately 9-fold of HP-β-CD. In contrast, however, the enhancing effect of T-1 on intestinal absorption of itraconazole was weaker than that of HP-β-CD. As one of reasons, the metabolism of T-1 in the intestine was observed. By chemical modification of T-1, more potent, safer and stable inclusion compound is expected.
|
Report
(4 results)
Research Products
(2 results)
